Full Text View
Tabular View
No Study Results Posted
Related Studies
Cholesterol Reduction in Seniors Program (CRISP)
This study has been completed.

First Received on October 27, 1999.   Last Updated on June 23, 2005   History of Changes
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00000477
  Purpose

To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due to the sequelae of atherosclerotic cardiovascular disease in older men and women.


Condition Intervention Phase
Atherosclerosis
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Hypercholesterolemia
Myocardial Ischemia
Drug: lovastatin
Phase II

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: July 1990
Estimated Study Completion Date: June 1992
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Men and women, ages 65 and older, with elevated low-density lipoprotein cholesterol levels between 159 and 221 mg/dl at entry.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000477

Sponsors and Collaborators
Investigators
Investigator: William Applegate University of Tennessee
Investigator: John Crouse Bowman Gray School of Medicine
Investigator: Donald Hunninghake University of Minnesota - Clinical and Translational Science Institute
Investigator: Robert Knopp University of Washington
Investigator: John LaRosa George Washington University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000477     History of Changes
Other Study ID Numbers: 66
Study First Received: October 27, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Atherosclerosis
Cardiovascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Coronary Disease
Heart Diseases
Hypercholesterolemia
Ischemia
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pathologic Processes
Lovastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 12, 2012